Peptide Database

Atrial Natriuretic Peptide · ANF

ANP (Atrial Natriuretic Peptide) is a 28-amino-acid cardiac hormone secreted by atrial cardiomyocytes in response to volume overload. It reduces blood pressure through natriuresis, vasodilation, and inhibition of the RAAS. Carperitide (synthetic ANP) is approved in Japan for acute heart failure. ANP is a key biomarker and drug target for heart failure and hypertension, studied alongside BNP and C-type natriuretic peptide.

Brain Natriuretic Peptide · Nesiritide

BNP (B-type/brain natriuretic peptide) is a 32-amino-acid hormone secreted by ventricular cardiomyocytes in response to wall stress and volume overload. Clinically, it is the primary biomarker for heart failure diagnosis and prognosis. Recombinant BNP (nesiritide/Natrecor) was approved for acute decompensated heart failure, producing vasodilation and natriuresis. Research into modified natriuretic peptides continues for heart failure therapy.

DDAVP · 1-desamino-8-D-arginine vasopressin

Desmopressin (DDAVP) is a synthetic vasopressin analog modified to eliminate vasopressor activity while retaining antidiuretic potency. FDA-approved for central diabetes insipidus, nocturnal enuresis (bedwetting), and von Willebrand disease, it achieves selective V2 receptor activation. Research explores its role in cognitive enhancement, where intranasal administration shows effects on memory consolidation.

Victoza · Saxenda

Liraglutide is a once-daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and obesity (Saxenda). It achieves fatty acid attachment to albumin for extended half-life, enabling daily dosing. The LEADER trial established significant cardiovascular mortality benefit in high-risk patients, and research continues into neuroprotective and anti-inflammatory properties beyond metabolic indications.

Ozempic · Wegovy

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.

ADH · Antidiuretic Hormone

Vasopressin (AVP) is a 9-amino-acid neuropeptide produced in the hypothalamus and released by the posterior pituitary. It regulates water reabsorption via V2 receptors in renal collecting ducts and vasoconstriction via V1a receptors in blood vessels. Clinically used for diabetes insipidus, septic shock vasodilation, GI hemorrhage, and cardiac arrest. Extensive research also examines its roles in social bonding, memory, and stress responses.